Navigation Links
Cardium Announces $4.0 Million Preferred Stock Financing And Reports On Exchange Listing Compliance
Date:4/5/2013

ue to be evaluated on an ongoing basis.

The initial closing covering the sale of 2,356 shares of Series A preferred stock, of approximately $2.35 million in gross proceeds, which is subject to the satisfaction of customary closing conditions, is expected to be completed on or about April 9, 2013. The second closing, covering the sale of 1,656 shares of Series A preferred stock, for an additional amount of approximately $1.65 million in gross proceeds, is contingent upon stockholder approval. In connection with the Securities Purchase Agreement, and in furtherance of the Company's NYSE MKT exchange listing compliance, Cardium has also agreed to seek stockholder approval for the company to effect a reverse stock split of its issued and outstanding common stock. The Company plans to submit proposals to approve the sale of the second tranche of 1,656 shares of Series A Preferred Stock and authorization for the proposed reverse stock split of its issued and outstanding common stock at Cardium's upcoming annual meeting of stockholders.  A more complete description of the terms and conditions of the financing will be available in the Form 8-K to be filed by the Company with the Securities and Exchange Commission.  The net proceeds from this transaction will be used for general working capital purposes. 

The preferred stock described above is being offered by the Company pursuant to a shelf registration statement that was filed by Cardium Therapeutics with the Securities and Exchange Commission (the "SEC") and declared effective by the SEC on August 27, 2010.  A prospectus supplement related to the offering was filed with the SEC on April 5, 2013.  Copies of the prospectus and accompanying prospectus supplement relating to the offering may be obtained from the SEC's website at http://www.sec.gov, or by request from Ladenburg Thalmann & Co., Inc., 4400 Biscayne Blvd., 14th Floor, Miami,
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Cardium Receives ISO Certification for Excellagen
2. Cardium Announces Presentaton at The 2013 Cell & Gene Therapy Forum
3. Cardium Presents Third Quarter 2012 Financial Results and Reports on Recent Developments
4. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
5. Cardium Presents Second Quarter 2012 Financial Results And Reports On Recent Developments
6. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
7. Cardium to Present at Sachs Associates 2012 Science, Partner, and Investment Forum: Gateway for the Global Life Sciences
8. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
9. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
10. MEI Pharma Announces $15.2 Million Registered Offering Of Common Stock
11. EntreMed Announces Changes to Board of Directors and CEO Appointment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... Aufgrund der enormen Nachfrage ... Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch die Jahre 2014 ... pharmaserialisation.com , zeigt die Serialisierungsanforderungen weltweit und ... treten. Für international tätige Unternehmen geht ... "ob", sondern darum, "wann" sie die neu in ...
(Date:9/19/2014)... , Sept. 19, 2014  Over 200 runners ... Future to Benefit the Radiation Oncology Institute (ROI), hosted ... at Golden Gate Park in San Francisco.  ... Moore , CEO of Radiation Business Solutions, "but ... have raised over $70,000 for the ROI this year. ...
(Date:9/19/2014)... -- Intarcia Therapeutics, Inc. today announced the ... candidate ITCA 650 (continuous subcutaneous delivery of exenatide) in ... at the 50 th Annual Meeting of the ... from the open-label, phase 3 FREEDOM-HBL (high baseline) trial ... with poorly controlled type 2 diabetes. The results were ...
Breaking Medicine Technology:Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 2Fifth Annual 5K Run for the Future to Benefit the Radiation Oncology Institute Breaks Attendance, Donation Records 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 2Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 3Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes 4
... Sept. 20 Cellectis bioresearch, the specialist in ... and Helix BioService & Consultants Pvt Ltd (Helix ... for the promotion of Cellectis bioresearch,s meganuclease-based products ... young company comprised of professionals with proven expertise ...
... JOSE, Calif., Sept. 17 Teikoku Pharma USA, Inc., ... U.S. Food and Drug Administration (FDA) has accepted for ... weekly transdermal patch of Aricept®, a leading medication for ... developed the weekly Aricept(r) patch based on a license ...
Cached Medicine Technology:Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 2Cellectis bioresearch and Helix Biocon Join Forces for the Promotion of cGPS® and cGPS® Custom Kits and Cell Line Engineering Services in India 3FDA Accepts Aricept® Patch (Donepezil Transdermal System) NDA for Review 2
(Date:9/19/2014)... Chino Hills, CA (PRWEB) September 19, 2014 ... the fastest-selling fitness boot camp in the country. He’s also ... mentoring thousands of clients, coaching celebrity trainers and serving as ... He knows marketing, and he says that becoming an integral ... camp’s success. , “One of the things that Fit Body ...
(Date:9/19/2014)... FL (PRWEB) September 19, 2014 ... Scott Theirl, a functional neurologist in private practice ... use of Prevagen Professional in older adults with ... Symposium – Focus On Brain Health conference ... Professional is the strongest formula available of the ...
(Date:9/19/2014)... September 19, 2014 ShopRite has launched ... School -- with the 2014-2015 school year. The new ... schools via eBoxTops and special donations throughout the year. ... school by registering their ShopRite Price Plus Card at ... for their favorite school. By using their Price Plus ...
(Date:9/19/2014)... 2014 Atlantic Information Services, Inc. (AIS) ... Directory of Health Plans — is pleased to announce ... 2014-2015. The latest edition of the annual book provides ... care industry. , With valuable intelligence on a ... benefit design and management strategies to corporate financial results ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 B. E. ... to healthcare providers, has been retained to lead a ... John’s Episcopal Hospital in Far Rockaway, N.Y. The top ... Smith has recently placed more than 900 healthcare executives ... a faith-based, full service community hospital serving the Rockaway ...
Breaking Medicine News(10 mins):Health News:New Post from Boot Camp Marketing Expert Bedros Keuilian Explains Importance of Becoming Part of the Community 2Health News:New Post from Boot Camp Marketing Expert Bedros Keuilian Explains Importance of Becoming Part of the Community 3Health News:Prevagen Research Presented at Healthcare Practitioner Conference 2Health News:ShopRite to Donate Up to $1 Million to Local Schools 2Health News:New Book from Atlantic Information Provides Insights Into Trends in the Health Care Industry 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 2Health News:St. John’s Episcopal Hospital Retains B. E. Smith to Recruit New COO 3
... Holdings,Inc. (NYSE: PAY ) today announced ... with Secure EDI,s state-of-the-art platform to consolidate,patient payments ... Secure EDI is a recognized market ... dental and institutional providers. The,company also creates seamless ...
... Annual Basic and Diluted Net Loss per Share of $1.87- ... or $4.77 per Diluted ShareSILVER SPRING, Md., Feb. 17 ... its financial results for the fourth quarter and year ended ... for 2008 grew in excess of 30% for the seventh ...
... extended as unlisted warrants to May 12, 2009 -BELLEVILLE, ... (TSX: BNC), a research-based, technology-driven Canadian biopharmaceutical company, announced ... the up to 8,203,334 common share purchase warrants issued ... March, 2007. 7,676,554 of these warrants, currently listed for ...
... FLORHAM PARK, N.J., Feb. 17 Shionogi & Co, ... velneperit, a novel neuropeptide Y (NPY) Y5 receptor antagonist ... of demonstrating a statistically significant reduction in body weight. ... the NPY Y5 receptor as a target for obesity ...
... 17 PAREXEL Consulting, a business unit ... leading global consultancy serving the biopharmaceutical and medical device ... of Principal Consultant in its European Product Development Practice. ... Sweden,s Medical Products Agency (MPA), will advise clients on ...
... N.Y., Feb. 17 New paintbrush makes painting ... ArroWorthy Co. NY, is designed to match the ... handle allows a variety of gripping areas for ... incorporated for on job resting or storage. White ...
Cached Medicine News:Health News:Secure EDI Integrates VeriFone IPCharge in Real Time Patient Payment and Claims Processing Solutions Suite 2Health News:Secure EDI Integrates VeriFone IPCharge in Real Time Patient Payment and Claims Processing Solutions Suite 3Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 2Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 3Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 4Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 5Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 6Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 7Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 8Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 9Health News:United Therapeutics Reports 2008 Fourth Quarter and Annual Financial Results 10Health News:Bioniche Warrants' Expiration Date to be Extended 2Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 2Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 3Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 4Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 5Health News:Shionogi Announces Positive Top-Line Efficacy Results from Year-Long Studies of Velneperit, a Novel NPY Y5 Receptor Antagonist Being Investigated for the Treatment of Obesity 6Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 2Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 3Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 4Health News:PAREXEL Consulting Enhances European Regulatory Affairs Capabilities With Appointment of Medical Products Agency Expert Dr. Anders Neil 5Health News:Efficient and Comfortable, the Right Brush(R) is the First Revolution in Painting Since the Roller 2Health News:Efficient and Comfortable, the Right Brush(R) is the First Revolution in Painting Since the Roller 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: